Comparative In-Vivo Wetting Characteristics of Silicone Hydrogel Materials With Selected Lens Care Systems

This study will be divided into two phases. In the Pre-Investigational Phase (Phase 1), participants will wear PureVision contact lenses for 30 days and use ReNu® Multiplus® for contact lens care. Eligible participants will continue into the Investigational Phase (Phase 2) and be randomly assigned to wear AIR OPTIX® AQUA contact lenses or ACUVUE® OASYS® with HYDRACLEAR® contact lenses for a total of two months. For contact lens care, participants will use OPTI-FREE® PUREMOIST® MPDS and BIOTRUE® for 30 days each.

Inclusion criteria

• Read and understand the Participant Information Sheet;
• Read, sign, and date the Informed Consent;
• Be a current silicone hydrogel contact lens wearer using the contact lenses under a frequent replacement (bi-weekly or monthly) daily wear modality;
• Be classified as symptomatic and a depositor at the end of the replacement period according to protocol-specified criteria;
• Agree to wear study contact lenses as directed for the duration of the study and maintain the appointment schedule;
• Best corrected visual acuity of 6/9 or better in each eye;
• Normal eyes with the exception of the need for visual correction;
• Other protocol-defined inclusion criteria may apply.

Exclusion criteria

• Known sensitivity or intolerance to any of the contact lenses or contact lens care products to be used;
• Monocular vision (only one eye with functional vision or only one eye fitted with contact lenses);
• Use of systemic medication which might interfere with contact lens wear or produce dry eye side effects;
• Systemic disease which might interfere with contact lens wear or produce dry eye side effects;
• Systemic or ocular allergies which might interfere with contact lens wear;
• Ocular disease which might interfere with contact lens wear;
• Active ocular infection;
• Use of any concomitant topical ocular medications during the study period;
• Previous ocular surgery;
• Pregnant, planning to become pregnant, or lactating at the time of enrollment;
• Participation in an investigational drug or device study within 30 days of entering this study;
• Other protocol-defined exclusion criteria may apply.